molecules of the month

The first, approved non-covalent BTKi, a next-generation oral SERD, a bioactive metabolite of a GHSR1a inverse agonist with the same therapeutic effect but different MOA to its parent are just some of the examples for this month's MOTM.

Learn more about the molecules by navigating to the full reviews on the right which cover: why the molecules matter, how they were discovered, the key steps behind optimization, how they work, why the targets were chosen, any interesting toxicology and clinical data, and more.

Sign up for our free weekly newsletter here to get more content like this straight to your inbox. Not a member? Get a free trial to check out substructure search and more features.